Evidence map›Paper›PMID 29682400›Full record

ArticleJournal of molecular biomarkers & diagnosis2017

Clinical Validation of a Serum Protein Panel (FLNA, FLNB and KRT19) for Diagnosis of Prostate Cancer.

Shobha Ravipaty, Wenfang Wu, Aditee Dalvi, Nikunj Tanna, Joe Andreazi, Tracey Friss, Allison Klotz, Chenchen Liao, Jeonifer Garren, Sally Schofield and 10 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of molecular biomarkers & diagnosis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 2 countries.

Shobha RavipatyBerg, LLC, 500 Old Connecticut Path Framingham, MA 01701, USA.
Wenfang WuBerg, LLC, 500 Old Connecticut Path Framingham, MA 01701, USA.
Aditee DalviBerg, LLC, 500 Old Connecticut Path Framingham, MA 01701, USA.
Nikunj TannaBerg, LLC, 500 Old Connecticut Path Framingham, MA 01701, USA.
Joe AndreaziBerg, LLC, 500 Old Connecticut Path Framingham, MA 01701, USA.
Tracey FrissBerg, LLC, 500 Old Connecticut Path Framingham, MA 01701, USA.
Allison KlotzBerg, LLC, 500 Old Connecticut Path Framingham, MA 01701, USA.
Chenchen LiaoBerg, LLC, 500 Old Connecticut Path Framingham, MA 01701, USA.
Jeonifer GarrenBerg, LLC, 500 Old Connecticut Path Framingham, MA 01701, USA.
Sally SchofieldBerg, LLC, 500 Old Connecticut Path Framingham, MA 01701, USA.
Eleftherios P DiamandisDepartment of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.
Eric A KleinGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, USA.
Albert DobiDepartment of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences and the Walter Reed Military Medical Center, Bethesda, Maryland, USA.
Shiv SrivastavaDepartment of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences and the Walter Reed Military Medical Center, Bethesda, Maryland, USA.
Poornima TekumallaBerg, LLC, 500 Old Connecticut Path Framingham, MA 01701, USA.
Michael A KiebishBerg, LLC, 500 Old Connecticut Path Framingham, MA 01701, USA.
Vivek VishnudasBerg, LLC, 500 Old Connecticut Path Framingham, MA 01701, USA.
Ranga Prasad SarangarajanBerg, LLC, 500 Old Connecticut Path Framingham, MA 01701, USA.
Niven R NarainBerg, LLC, 500 Old Connecticut Path Framingham, MA 01701, USA.
Viatcheslav R AkmaevBerg, LLC, 500 Old Connecticut Path Framingham, MA 01701, USA.
Cleveland Clinic · USMount Sinai Hospital · CA

Funding

Cell Specific Expression Signatures in Prostate CancerR01DK065977 · NIDDK · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI SRIVASTAVA, SHIV · 2004 to 2007
$688k
NIDDK NIH HHS R01 DK065977
6 · The paper itself

Abstract

This study reports on the development of a novel serum protein panel of three prostate cancer biomarkers, Filamin A, Filamin B and Keratin-19 (FLNA, FLNB and KRT19) using multivariate models for disease screening and prognosis. ELISA and IPMRM (LC-MS/MS) based assays were developed and analytically validated by quantitative measurements of the biomarkers in serum. Retrospectively collected and clinically annotated serum samples with PSA values and Gleason scores were analyzed from subjects who underwent prostate biopsy, and showed no evidence of cancer with or without indication of prostatic hyperplasia, or had a definitive pathology diagnosis of prostatic adenocarcinoma. Probit linear regression models were used to combine the analytes into score functions to address the following clinical questions: does the biomarker test augment PSA for population screening? Can aggressive disease be differentiated from lower risk disease, and can the panel discriminate between prostate cancer and benign prostate hyperplasia? Modelling of the data showed that the new prostate biomarkers and PSA in combination were better than PSA alone in identifying prostate cancer, improved the prediction of high and low risk disease, and improved prediction of cancer versus benign prostate hyperplasia.

Indexed as

BiomarkerFLNAFLNBKRT19Prostate cancerProstate specific antigen

Identifiers

PMID29682400
PMCPMC5909981
OpenAlexW2606920884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.